FDA approves Lexiscan injection for testing of coronary artery disease
CVT Therapeutics Inc. has received FDA approval for its injection for the detection of coronary artery disease . The Lexiscan injection is designed as a pharmacologic stress agent in the testing to detect and characterize coronary artery disease for patients who are unable to undergo adequate exercise stress.
-
Cardiac Respiratory Stress Test Can Quickly Detect Significant Coronary Artery Disease
Abbott Wins CE Markings for its XIENCE PRIME(TM)Everolimus Eluting Coronary Stent System
Study Finds Increased Presence, Severity Of Coronary Artery Plaques In HIV-Infected Men
FDA approves JBAIDS testing device
FDA’s expanded indication for Chembio’s POC testing
